Cargando…
The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins
Ritonavir, originally developed as HIV protease inhibitor, is widely used as a booster in several HIV pharmacotherapy regimens and more recently in Covid-19 treatment (e.g., Paxlovid). Its boosting capacity is due to the highly potent irreversible inhibition of the cytochrome P450 (CYP) 3 A enzyme,...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Authors. Published by Elsevier Masson SAS.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065864/ https://www.ncbi.nlm.nih.gov/pubmed/37004323 http://dx.doi.org/10.1016/j.biopha.2023.114636 |